Cerebral oedema

G6_CEROEDEMA

brain disease: A disease affecting the brain or part of the brain.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — G93.6 Hospital discharge: ICD-9 — 3485 Cause of death: ICD-10 — G93.6 Cause of death: ICD-9 — 3485 2 out of 7 registries used, show all original rules.	65
4. Check minimum number of events None	65
5. Include endpoints None	65
6. Filter based on genotype QC (FinnGen only)	65

Control definitions (FinnGen only)

Control exclude: G6_OTHNEU

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: G93
Name in latin: Oedema cerebri

NAME	G6_CEROEDEMA
CONTROL_EXCLUDE	G6_OTHNEU
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	G936
HD_ICD_9	3485
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	G936
COD_ICD_9	3485
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Cerebral oedema based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	918	430	478
Only index persons	515	232	283
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	50.49	52.34	48.62
Only index persons	51.71	52.78	50.83

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	65	31	34
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	54.83	54.33	55.29

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
61: Matched controls
610

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

G93.6

ICD-10 Finland

Cerebral oedema

+∞

82.2

N03AX14

ATC

levetiracetam; systemic

59.8

20.3

AAB10

NOMESCO Finland

Partial excision of intracranial lesion

64.9

13.5

L01AX03

ATC

temozolomide; systemic

162.0

13.0

182

Kela drug reimbursment

Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide

35.5

11.3

AA1AD

NOMESCO Finland

CT of head and brain

7.7

11.1

H02AB02

ATC

dexamethasone; systemic

10.1

10.2

130

Kela drug reimbursment

Malignant tumour

11.0

9.8

AA1CG

NOMESCO Finland

Extensive MRI examination of brain with high intensity magnet

12.6

9.5

111

Kela drug reimbursment

Epilepsy and comparable convulsive disorders

12.6

9.5

WX700

NOMESCO Finland

Respiratory and circulatory monitoring

7.6

9.1

G40.29

ICD-10 Finland

Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures

26.3

8.4

WX882

NOMESCO Finland

High dependency care

18.2

8.1

WX872

NOMESCO Finland

Intensive care

18.7

7.6

AAK00

NOMESCO Finland

Cranioplasty

+∞

7.4

AAK80

NOMESCO Finland

Partial excision of skull cap

+∞

7.4

R51.80

ICD-10 Finland

Headache

6.6

7.4

WF003

NOMESCO Finland

Adjuvant radiotherapy

34.5

7.4

N03AX18

ATC

lacosamide; systemic

45.2

6.9

GD1UA

NOMESCO Finland

Thorax X-ray examination outside radiological department

5.6

6.8

AA1BG

NOMESCO Finland

Standard MRI examination of brain with high intensity magnet

7.9

6.7

GD1QA

NOMESCO Finland

Supine thorax X-ray examination

6.3

6.6

ZXC95

NOMESCO Finland

Use of surgical navigator

30.1

6.4

C71.10

ICD-10 Finland

Malignant tumor in frontal lobe without histology

+∞

6.3

AAF00

NOMESCO Finland

Ventriculostomy

+∞

6.3

TPH04

NOMESCO Finland

Cathetrisation of vein

5.0

6.1

WF002

NOMESCO Finland

Radical radiotherapy

17.2

6.1

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(4035726)

10.29

17.00

1.5

1.4

—

(3003396) Base excess in Arterial blood by calculation

7.36

13.27

11.3

5.6

1.7

0.8

mmol/l

0.67

(3019473) Protein [Mass/volume] in Cerebral spinal fluid

11.09

10.20

2.9

1.5

642.7

409.3

mg/l

1.03

(40766799) MGMT gene methylation score in Tissue by Molecular genetics method

+∞

9.60

1.0

0.0

—

(3044290) Cell count panel - Cerebral spinal fluid

17.63

8.63

2.8

2.0

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

6.82

7.39

18.8

7.1

—

(3023368) Bacteria identified in Blood by Culture

125

3.83

6.56

5.4

4.2

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

3.75

5.49

4.7

2.2

106.4

177.8

ng/l

0.27

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

4.83

5.18

26.6

11.3

24.0

24.5

mmol/l

0.18

(3019060) Gas panel - Arterial blood

4.67

4.99

14.8

2.7

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

3.57

4.82

2.7

1.8

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

219

3.15

4.80

4.8

3.7

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

3.30

4.75

3.0

2.2

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

3.76

4.25

2.4

1.5

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

3.28

3.97

4.2

3.1

4.2

2.6

e6/l

—

(3044640) Blood type and Crossmatch panel - Blood

147

2.76

3.80

3.1

2.1

—

(1761868) Lipid panel - Serum or Plasma

209

0.26

3.74

3.1

2.6

—

(3032080) INR in Blood by Coagulation assay

181

2.67

3.68

9.1

7.1

1.4

1.2

inr

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

3.37

3.44

2.4

1.5

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

5.91

3.30

2.1

2.7

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

4.57

3.01

1.8

1.6

—

(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing

8.89

2.79

1.0

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

8.89

2.79

1.2

1.0

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

7.61

2.59

1.2

1.0

—

(3014007) Fractional oxyhemoglobin in Arterial blood

3.19

2.42

7.1

7.0

94.8

92.5

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

6.65

2.41

2.2

2.0

—

(42870588) Differential panel, method unspecified - Blood

177

2.15

2.30

17.5

6.0

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

307

2.18

2.26

22.8

10.1

3.8

4.1

e9/l

0.37

264

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

2.47

2.25

3.9

2.7

1.0

0.8

e6/l

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

278

2.14

2.25

14.2

5.7

11.6

11.4

umol/l

0.06

264

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

4.00

2.22

3.3

2.3

95.7

95.5

—

(3026008) Bacteria identified in Urine by Culture

130

2.19

4.3

2.7

—

(3018418) pH of Serum or Plasma

133

2.13

2.06

3.1

3.6

—

7.4

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

4.02

1.98

3.7

2.9

259.5

162.6

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

4.82

1.98

2.0

1.8

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

4.82

1.98

2.0

1.8

—

(3005719) IgG [Mass/volume] in Serum or Plasma

2.77

1.94

5.3

2.3

11.7

10.2

g/l

—

(3001604) Monocytes [#/volume] in Blood

251

1.97

1.90

13.8

6.6

0.6

e9/l

0.92

216

(3006315) Basophils [#/volume] in Blood

251

1.97

1.90

14.1

6.6

0.0

e9/l

0.26

220

(40768804) Tissue Pathology biopsy report

190

1.95

1.81

2.7

1.9

—

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

173

1.96

1.80

4.0

3.4

63.0

31.3

u/l

0.63

160

(3003694) ABO and Rh group [Type] in Blood

134

1.97

1.67

1.2

1.4

—

(40761535) Cells panel - Urine sediment

0.00

1.59

0.0

3.5

—

(3000991) Gas panel - Venous blood

2.44

1.55

21.1

9.8

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

485

0.54

1.48

30.3

11.4

89.2

84.6

ml/min/173m2

0.67

385

(3002582) Erythrocytes [#/volume] in Urine

142

1.83

1.38

5.4

3.5

11.1

77.7

e6/l

1.28

113

(43055554) Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation

2.27

1.37

35.1

8.3

1.8

0.9

mmol/l

—

(3018095) Leukocytes [#/volume] in Urine

172

1.74

1.26

6.4

4.0

13.4

104.4

e6/l

1.91

120

(3042936) Bacteria identified in Isolate by Culture

1.98

1.21

2.6

1.9

—

(3030467) Casts [#/volume] in Urine by Automated count

127

1.70

1.04

5.4

3.3

0.2

0.3

e6/l

0.16

(3000494) Fungus identified in Specimen by Culture

1.93

1.01

1.6

1.4

—

(3012544) pH of Venous blood

1.93

0.94

15.9

5.3

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.17

0.92

1.0

1.3

—

(36304419) Bacteria [Presence] in Urine

124

1.62

0.87

5.4

3.2

—

(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

560

0.59

0.87

21.6

10.0

39.0

26.8

u/l

1.46

548

(3022313) Gas panel - Capillary blood

2.03

0.87

47.7

9.8

—

(3031040) Bacteria [#/volume] in Urine by Automated count

323

1.52

0.84

6.7

4.0

—

657.8

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

567

0.59

0.82

39.7

14.3

65.0

77.0

umol/l

3.85

567

(3016888) Borrelia burgdorferi IgG Ab [Units/volume] in Serum

1.90

0.81

1.3

1.2

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.79

0.0

1.7

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

200

1.50

0.78

2.9

3.7

16.8

37.0

ng/l

1.06

134

(3037467) Urinalysis macro (dipstick) panel - Urine

347

1.49

0.76

6.4

4.2

—

(40758558) Short blood count panel - Blood

128

1.56

0.76

25.1

6.7

—

(3019225) pH of Specimen

1.89

0.75

3.7

5.4

—

(3000330) Specific gravity of Urine by Test strip

2.00

0.72

4.0

3.3

—

(3004490) Bicarbonate [Moles/volume] standard in Capillary blood

1.85

0.67

62.4

9.6

25.7

24.1

mmol/l

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

1.72

0.62

2.2

0.9

1.6

—

(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method

0.00

0.61

0.0

1.9

—

3.1

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.61

0.0

2.0

—

(4094501)

0.00

0.61

0.0

1.1

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.73

0.58

2.5

1.7

—

(3007853) Bacteria identified in Skin by Aerobe culture

1.55

0.57

2.8

1.5

—

(3021589) Normoblasts [#/volume] in Blood

221

1.38

0.55

20.1

9.3

0.0

e9/l

0.48

172

(3020682) Albumin/Creatinine [Ratio] in Urine

128

1.44

0.55

4.4

3.6

1.8

6.9

mg/mmol

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

165

1.40

0.54

5.5

3.4

—

(3013512) EKG study

133

1.38

0.44

3.3

3.9

—

(3008401) Mugwort IgE Ab [Units/volume] in Serum

0.00

0.42

0.0

1.0

—

1.3

—

(4034850)

0.00

0.41

0.0

7.9

—

(3023351) European house dust mite IgE Ab [Units/volume] in Serum

0.00

0.41

0.0

1.1

—

2.0

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.41

0.0

1.3

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.41

0.0

1.3

—

(3003888) Timothy IgE Ab [Units/volume] in Serum

0.00

0.41

0.0

1.0

—

8.4

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

375

0.80

0.32

3.4

—

(3015736) pH of Urine

207

1.25

0.31

3.6

3.4

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

179

1.26

0.30

2.6

1.9

100.3

99.4

pmol/l

0.04

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.33

0.26

1.4

1.7

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

2.7

—

16.6

—

(3039162) Centromere protein B Ab [Units/volume] in Serum

0.00

0.21

0.0

1.2

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.21

0.0

1.5

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.21

0.0

2.3

—

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

0.00

0.21

0.0

1.5

—

(3025245) SCL-70 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(36660697) Celiac disease serology panel - Serum

1.30

0.21

1.2

—

(3036086) Jo-1 extractable nuclear Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.25

0.20

1.0

1.5

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.73

0.18

2.2

2.1

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

0.71

0.18

3.8

6.3

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

0.70

0.18

2.8

1.4

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

122

1.19

0.15

4.2

3.4

—

(40761511) CBC panel - Blood by Automated count

547

0.83

0.15

29.5

11.5

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

537

0.84

0.14

46.3

14.2

4.0

mmol/l

0.05

527

(3041096) Erythrocytes [Presence] in Urine by Automated

145

1.14

0.10

3.2

3.5

—

(3021960) Folate [Moles/volume] in Serum or Plasma

114

0.85

0.10

1.7

1.5

19.2

22.5

nmol/l

—

(3009542) Hematocrit [Volume Fraction] of Blood

495

0.88

0.10

44.6

12.7

38.8

41.2

0.97

386

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

1.07

0.09

5.2

4.6

10.0

10.7

ug/l

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

107

1.15

0.09

1.3

1.7

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

107

1.15

0.09

1.7

2.1

—

(40768797) Stomach Pathology biopsy report

0.82

0.08

2.0

1.2

—

(3019550) Sodium [Moles/volume] in Serum or Plasma

532

0.89

0.07

46.7

14.1

138.5

139.7

mmol/l

1.95

523

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

132

0.89

0.07

2.3

3.9

23.3

20.5

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.05

0.07

1.2

1.6

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

202

0.92

0.06

4.1

3.8

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

519

1.11

0.06

39.0

13.2

23.4

21.6

mg/l

0.15

395

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

370

0.94

0.04

3.3

4.1

16.6

14.9

pmol/l

2.55

344

(3002385) Erythrocyte distribution width [Ratio]

437

0.95

0.01

49.7

14.8

13.7

13.5

0.47

427

(3044889) 12 lead EKG panel

341

0.99

0.00

3.1

3.4

—

(3042631) Mycobacterium sp identified in Specimen

0.00

0.0

5.7

—

(3017315) Amylase [Enzymatic activity/volume] in Urine

0.00

0.0

1.3

—

120.7

—

(3041642) Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

1.0

—

(3040359) Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3038546) Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3035933) Granulocytes/100 leukocytes in Blood

0.00

0.0

1.0

—

(3021952) Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability

0.00

0.0

1.3

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

0.0

2.7

—

(3025130) Human papilloma virus identified in Specimen

0.00

0.0

1.3

—

(3014037) CD3+CD4+ (T4 helper) cells/100 cells in Blood

0.00

0.0

3.3

—

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

0.00

0.0

8.1

—

62.3

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

0.00

0.0

1.5

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

6.5

—

198.8

—

(3013290) Carbon dioxide [Partial pressure] in Blood

0.00

0.0

1.8

—

4.9

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.0

1.4

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

0.0

1.5

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

0.00

0.0

1.6

—

(3003740) Influenza virus B Ag [Presence] in Specimen

0.00

0.0

1.3

—

(3040363) Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.2

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.0

1.1

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.1

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

0.0

1.0

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.0

1.1

—

(3002523) Influenza virus A Ag [Presence] in Specimen

0.00

0.0

1.3

—

(40762119) U1 small nuclear ribonucleoprotein 70kD Ab [Units/volume] in Serum

0.00

0.0

1.2

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

0.00

0.0

1.5

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.00

0.0

1.7

—

(3021788) Differential panel - Synovial fluid

0.00

0.0

1.8

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

0.00

0.0

1.6

—

1.0

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

0.00

0.0

6.0

—

4.5

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

0.00

0.0

1.0

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

0.00

0.0

1.9

—

34.3

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.98

0.00

1.8

—

(3004616) Nuclear Ab [Presence] in Serum

0.00

0.0

1.2

—

(40771527) Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection

0.00

0.0

1.8

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.1

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

0.0

1.5

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.0

1.0

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.0

1.1

—

(3022806) Fractional oxyhemoglobin in Capillary blood

0.00

0.0

1.2

—

91.1

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

5.0

—

32.1

—

(3027315) Oxygen [Partial pressure] in Blood

0.00

0.0

1.8

—

9.4

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.0

1.1

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.0

1.6

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.0

1.1

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum

0.00

0.0

1.2

—

(40768800) Prostate Pathology biopsy report

0.00

0.0

1.4

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

0.00

0.0

1.5

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.1

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.0

1.3

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.00

0.0

1.6

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

0.0

1.4

—

(3027456) Digoxin [Moles/volume] in Serum or Plasma

0.00

0.0

4.2

—

0.8

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

0.00

0.0

1.5

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.0

1.3

—

Mortality – FinRegistry

↥

Association

Association between endpoint G6_CEROEDEMA and mortality.

Females

Parameter	HR [95% CI]	p-value
G6_CEROEDEMA	9.279 [2.77, 31.05]	< 0.001
Birth year	0.99 [0.98, 1.0]	0.032

During the follow-up period (1.1.1998 — 31.12.2019), 68 out of 166 females with G6_CEROEDEMA died.

Males

Parameter	HR [95% CI]	p-value
G6_CEROEDEMA	10.985 [5.1, 23.68]	< 0.001
Birth year	0.989 [0.98, 1.0]	0.023

During the follow-up period (1.1.1998 — 31.12.2019), 79 out of 184 males with G6_CEROEDEMA died.

Mortality risk

Mortality risk for people of age

years, who have G6_CEROEDEMA.

N-year risk	Females	Males
1	0.852%	1.959%
5	4.155%	10.695%
10	11.262%	27.797%
15	21.457%	48.394%
20	33.987%	69.973%

Relationships between endpoints

↥

Index endpoint: G6_CEROEDEMA – Cerebral oedema

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Cerebral oedema

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints